stockrowBruker Corporation
BRKR Healthcare Medical Devices
Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.
- Revenue
- +1.57%
- EPS
- −75.4%
- Free cash flow
- +278.7%
- Total debt
- −14.7%
Quarter to September 2026, against a year earlier
Follow BRKR
Alert me
Bruker Corporation (BRKR) Revenue
Bruker Corporation's revenue for fiscal 2025 was $3.4B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $3.5B. Over the past ten years it has ranged from $1.6B (fiscal 2016) to $3.4B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. Bruker Corporation ranks 12th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.4B | 2.08% |
| FY2024 | $3.4B | 13.56% |
| FY2023 | $3.0B | 17.14% |
| FY2022 | $2.5B | 4.67% |
| FY2021 | $2.4B | 21.66% |
| FY2020 | $2.0B | (4.11%) |
| FY2019 | $2.1B | 9.34% |
| FY2018 | $1.9B | 7.34% |
| FY2017 | $1.8B | 9.59% |
| FY2016 | $1.6B | (0.77%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $874.0M | 4.23% |
| Jun 2026 | $838.5M | 1.83% |
| Mar 2026 | $823.4M | (15.74%) |
| Dec 2025 | $977.2M | 13.56% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $10.5B |
| BRKR Bruker Corporation | $3.5B |
| PODD Insulet Corporation compare | $3.2B |
| GMED Globus Medical, Inc. compare | $3.1B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $2.6B |
| BIO Bio-Rad Laboratories, Inc. compare | $2.6B |
| PEN Penumbra, Inc. compare | $1.6B |
| GKOS Glaukos Corporation compare | $690.3M |
| TXG 10x Genomics compare | $616.9M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BRKR
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement